M
Marianne J. Ellis
Researcher at University of Bath
Publications - 54
Citations - 1531
Marianne J. Ellis is an academic researcher from University of Bath. The author has contributed to research in topics: PLGA & Bioreactor. The author has an hindex of 21, co-authored 52 publications receiving 1193 citations. Previous affiliations of Marianne J. Ellis include University of Manchester & Cardiff University.
Papers
More filters
Journal ArticleDOI
Bringing cultured meat to market: Technical, socio-political, and regulatory challenges in cellular agriculture
Neil Stephens,Lucy Di Silvio,Illtud Dunsford,Marianne J. Ellis,Abigail Glencross,Alexandra E. Sexton +5 more
TL;DR: Cultured meat is a promising, but early stage, technology with key technical challenges including cell source, culture media, mimicking the in-vivo myogenesis environment, animal-derived and synthetic materials, and bioprocessing for commercial-scale production.
Journal ArticleDOI
Effects of common sterilization methods on the structure and properties of poly(D,L lactic-co-glycolic acid) scaffolds.
TL;DR: The results of this study suggest that antibiotic treatment shows the most potential to sterilize PLGA hollow fibers for tissue engineering.
Journal ArticleDOI
Poly(lactic-co-glycolic acid) hollow fibre membranes for use as a tissue engineering scaffold.
TL;DR: The PDLLGA hollow fibres are a promising scaffold to address the size limitations currently seen in tissue engineered constructs, and varying the air gap and temperature when spinning changed the morphology of the fibres.
Journal ArticleDOI
Bioprocess Design Considerations for Cultured Meat Production With a Focus on the Expansion Bioreactor
TL;DR: This review highlights the vital aspects of a cultured meat bioreactor design that are often overlooked when parallels are drawn against fermentation processes such as brewing or recombinant protein production in the pharmaceutical industry.
Journal ArticleDOI
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
Christopher McCabe,Lothar Bergmann,N. Bosanquet,Marianne J. Ellis,Harald Enzmann,M. von Euler,B. Jonsson,K.-J. Kallen,D. Newling,V. Nüssler,B. Paschen,R. de Wilde,Nils Wilking,C. Teale,Heinz Zwierzina +14 more
TL;DR: Outcomes of the meeting were a greater understanding of the barriers facing drug developers in an evolving postregulatory world, clarity about what regulatory and postreg regulatory bodies expect to see in dossiers of new anticancer agents as they contemplate licensure and reimbursement, and several sets of recommendations to optimize patients' access to innovative, safe, effective, and fairly priced cancer treatments.